A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis

Trial Profile

A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Jun 2017

At a glance

  • Drugs Teriflunomide (Primary)
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use
  • Acronyms TOWER
  • Sponsors Sanofi
  • Most Recent Events

    • 27 Jun 2017 Results (n=1031) of TOWER core and extension studies, presented at the 3rd Congress of the European Academy of Neurology.
    • 28 Apr 2017 Results analysing the impact of long term treatment with Teriflunomide on disability outcomes from TEMSO and TOWER and their extension studies, presented at the 69th Annual Meeting of the American Academy of Neurology
    • 28 Apr 2017 Results of a pooled analysis in patients with progressive and relapsing MS from two randomized trials and their extensions (TEMSO and TOWER; n=122), presented at the 69th Annual Meeting of the American Academy of Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top